公開日期 | 標題 | 作者 | 來源出版物 | WOS | 全文 |
2015 | Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms | Narayan, R.; Benjamin, J.; Laport, G.; Tian, L.; Tate, K.; Elder, L.; Galvez, L.; Armstrong, R.; Sheehan, K.; Lowsky, R.; Arai, S.; Johnston, L.; Miklos, D.; Muffly, L. S.; Rezvani, A. R.; Shizuru, J.; Wen-Kai Weng ; Strober, S.; Negrin, R.; Meyer, E. | Blood | | |
2013 | Early Infusion Of Donor-Derived CIK Cells As Consolidative Immunotherapy Following Non-Myeloablative Allogeneic Transplantation: Safety and Feasibility | Benjamin, J.; Laport, G. G.; Tate, K.; Galvez, L.; Armstrong, R.; Sheehan, K.; Arai, S.; Lowsky, R.; Johnston, L.; Miklos, D. B.; Shizuru, J.; Wen-Kai Weng ; Negrin, R. | Blood | | |
2018 | Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma | Spiegel, J. Y.; Sahaf, B.; Hossain, N.; Frank, M. J.; Claire, G.; Abramian, M.; Latchford, T.; Villa, B.; Cancilla, J.; Oak, J.; Natkunam, Y.; Long, S. R.; Arai, S.; Johnston, L. J.; Lowsky, R.; Meyer, E. H.; Muffly, L. S.; Negrin, R. S.; Rezvani, A. R.; Shizuru, J. A.; Wen-Kai Weng ; Kong, K. A.; Mackall, C. L.; Miklos, D. B. | Blood | | |
2014 | European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation | Medeiros, B. C.; Tian, L.; Robenson, S.; Laport, G. G.; Johnston, L. J.; Shizuru, J. A.; Miklos, D. B.; Arai, S.; Benjamin, J. E.; Wen-Kai Weng ; Negrin, R. S.; Lowsky, R. | Blood Cancer Journal | | |
2017 | HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity | Spinner, M. A.; Fernandez-Vina, M.; Creary, L. E.; Quinn, O.; Elder, L.; Arai, S.; Johnston, L. J.; Meyer, E. H.; Miklos, D. B.; Muffly, L. S.; Negrin, R. S.; Shizuru, J. A.; Wen-Kai Weng ; Laport, G. G.; Strober, S.; Lowsky, R.; Rezvani, A. R. | Blood Advances | | |
2018 | Infusion of donor-derived CD8(+) memory T cells for relapse following allogeneic hematopoietic cell transplantation | Muffly, L.; Sheehan, K.; Armstrong, R.; Jensen, K.; Tate, K.; Rezvani, A. R.; Miklos, D.; Arai, S.; Shizuru, J.; Johnston, L.; Meyer, E.; Wen-Kai Weng ; Laport, G. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood Advances | | |
2016 | Long-Term Outcomes of AML Patients Using Total Lymphoid Irradiation with Anti-Thymocyte Globulin | Nakasone, H.; Miklos, D. B.; Meyer, E.; Rezvani, A.; Muffly, L.; Wen-Kai Weng ; Arai, S.; Johnston, L.; Laport, G. G.; Shizuru, J. A.; Negrin, R.; Strober, S.; Lowsky, R. | Biology of Blood and Marrow Transplantation | | |
2016 | Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma | Neppalli, A. K.; Shizuru, J.; Johnston, L. J.; Muffly, L. S.; Wen-Kai Weng ; Negrin, R.; Meyer, E.; Laport, G.; Lowsky, R.; Arai, S.; Miklos, D. B.; Rezvani, A. R. | Journal of Clinical Oncology | | |
2014 | Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS) | Wen-Kai Weng ; Armstrong, R.; Arai, S.; Johnston, L.; Laport, G. G.; Lowsky, R.; Miklos, D. B.; Shizuru, J. A.; Benjamin, J. E.; Negrin, R. S.; Reddy, S.; Million, L.; Hoppe, R. T.; Kim, Y. H. | Blood | | |
2012 | Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms | Benjamin, J.; Chhabra, S.; Kohrt, H. E.; Laport, G. G.; Arai, S.; Johnston, L.; Miklos, D. B.; Shizuru, J. A.; Wen-Kai Weng ; Negrin, R. S.; Lowsky, R. | Blood | | |
2020 | Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma | Wen-Kai Weng ; Arai, S.; Rezvani, A.; Johnston, L.; Lowsky, R.; Miklos, D.; Shizuru, J.; Muffly, L.; Meyer, E.; Negrin, R. S.; Wang, E.; Almazan, T.; Million, L.; Khodadoust, M.; Li, S. F.; Hoppe, R. T.; Kim, Y. H. | Blood Advances | | |
2018 | Nonmyeloablative Allogeneic Transplantation Using TLI-ATG Conditioning for Lymphoid and Myeloid Malignancies: Mature Follow-up from a Large, Single Institution Cohort | Spinner, M. A.; Kennedy, V. E.; Tamaresis, J. S.; Lavori, P. W.; Elder, L. V.; Arai, S.; Johnston, L. J.; Meyer, E. H.; Miklos, D. B.; Muffly, L. S.; Negrin, R. S.; Rezvani, A. R.; Shizuru, J. A.; Wen-Kai Weng ; Hoppe, R. T.; Strober, S.; Lowsky, R. | Blood | | |
2019 | Nonmyeloablative TLI-ATG conditioning for allogeneic transplantation: mature follow-up from a large single-center cohort | Spinner, M. A.; Kennedy, V. E.; Tamaresis, J. S.; Lavori, P. W.; Arai, S.; Johnston, L. J.; Meyer, E. H.; Miklos, D. B.; Muffly, L. S.; Negrin, R. S.; Rezvani, A. R.; Shizuru, J. A.; Wen-Kai Weng ; Hoppe, R. T.; Strober, S.; Lowsky, R. | Blood Advances | | |
2014 | Outcome of Tandem Autologous/Allogeneic Hematopoietic Cell Transplantation in High-Risk Non Hodgkin's Lymphoma Patients: Stanford University Experience | Wudhikarn, K.; Lavori, P.; Arai, S.; Johnston, L.; Laport, G. G.; Lowsky, R.; Miklos, D. B.; Shizuru, J. A.; Hoppe, R. T.; Benjamin, J.; Meyer, E.; Negrin, R.; Wen-Kai Weng | Biology of Blood and Marrow Transplantation | | |
2013 | Outcomes After Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation with Total Lymphoid Irradiation and Anti-Thymocyte Globulin in Lymphoid Malignancies After Failed Autologous Transplantation | Kanate, A. S.; Efron, B.; Chhabra, S.; Kohrt, H.; Shizuru, J. A.; Laport, G. G.; Miklos, D. B.; Benjamin, J.; Johnston, L.; Arai, S.; Wen-Kai Weng ; Negrin, R.; Strober, S.; Lowsky, R. | Biology of Blood and Marrow Transplantation | | |
2008 | Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Non-Myeloablative Conditioning with Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) Confirm a Low Incidence of Graft Versus Host Disease (GVHD) with Retained Anti-Tumor Activity | Kohrt, H.; Turnbull, B.; Laport, G.; Miklos, D.; Shizuru, J.; Johnston, L.; Arai, S.; Wen-Kai Weng ; Benjamin, J.; Blume, K.; Negrin, R.; Lavori, P.; Strober, S.; Lowsky, R. | Blood | | |
- | Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma | Lemieux, C.; Muffly, L. S.; Rezvani, A.; Lowsky, R.; Iberri, D. J.; Craig, J. K.; Frank, M. J.; Johnston, L. J.; Liedtke, M.; Negrin, R.; Wen-Kai Weng ; Meyer, E.; Shizuru, J.; Shiraz, P.; Arai, S.; Miklos, D. B.; Sidana, S. | Bone Marrow Transplantation | | |
2016 | Phase I Study of CD8 Memory T-Cell Donor Lymphocyte Infusion for Relapse of Hematologic Malignancies Following Matched Related Donor Allogeneic Hematopoietic Cell Transplantation | Muffly, L. S.; Sheehan, K.; Armstrong, R.; Tate, K.; Tudisco, C.; Rezvani, A. R.; Miklos, D.; Arai, S.; Shizuru, J.; Johnston, L.; Meyer, E.; Wen-Kai Weng ; Laport, G. G.; Negrin, R. S.; Strober, S.; Lowsky, R. | Blood | | |
2018 | Phase I/II Trial for Patients with Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT with a T Cell Depleted Graft with Infusion of Conventional T Cells and Regulatory T Cells | Meyer, E.; Laport, G. G.; Tantsura, I.; Tang, S. W.; Sahaf, B.; Rangarajan, K.; Armstrong, R.; Tate, K.; Tudisco, C.; Sheehan, K.; Arai, S.; Johnston, L.; Muffly, L.; Lowsky, R.; Rezvani, A.; Wen-Kai Weng ; Miklos, D.; Negrin, R. S. | Biology of Blood and Marrow Transplantation | | |
2008 | Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma | Arai, S.; Letsinger, R.; Johnston, L.; Laport, G.; Lowsky, R.; Miklos, D.; Shizuru, J.; Wen-Kai Weng ; Wong, R.; Lavori, P.; Blume, K.; Negrin, R.; Horning, S. | Blood | | |